Immunomedics recently announced that Trodelvy (sacituzumab govitecan-hziy) is now available through major specialty distributors in the U.S. and that the first patient was treated on April 29, 2020. Immunomedics works to deliver breakthrough therapies to help transform the lives of those with hard-to-treat cancers.
Trodelvy is the first anti-Trop-2 ADC recently approved by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease.
Immunomedics was able to make Trodelvy available to people with Metastatic triple-negative breast cancer (mTNBC) shortly upon FDA approval. Also, Immunomedics’ regulatory and market access teams completed the national drug rebate agreement with the CMS. States, for Medicaid specifically, are now generally obligated to cover Trodelvy as of July 1, 2020.
Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, was selected to be the sole distributor of TRODELVY™ from Immunomedics.
Biologics specialty pharmacy, as part of McKesson Life Sciences, a business within McKesson, is recognized for its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.
Takeaway: Biologics by McKesson is cornering the specialty pharmacy limited distribution market for new oncology drugs